Mild cognitive impairment: Prevalence, prognosis, aetiology, and treatment

Research output: Contribution to journalArticle

351 Citations (Scopus)

Abstract

Mild cognitive impairment (MCI) is a recently described syndrome that is currently thought of as a transition phase between healthy cognitive ageing and dementia. Although this notion seems to be reasonable, the general nature of the term MCI - including its many definitions - makes accurate accounting of the prevalence, prognosis, and potential benefit from treatment somewhat difficult. The differences in cognitive profile and clinical progression among individuals with MCI are generally recognised. However, recent evidence also suggests that the aetiological heterogeneity among individuals with MCI could be greater than previously reported. For example, cerebrovascular disease seems to be underestimated as a potential cause of MCI. In this review, I attempt to recognise workable definitions of MCI to discuss the prevalence, pathophysiology, prognosis, and possibilities for treatment of this disorder.

Original languageEnglish (US)
Pages (from-to)15-21
Number of pages7
JournalLancet Neurology
Volume2
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Therapeutics
Cerebrovascular Disorders
Phase Transition
Dementia
Cognitive Dysfunction
Cognitive Aging

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Mild cognitive impairment : Prevalence, prognosis, aetiology, and treatment. / DeCarli, Charles.

In: Lancet Neurology, Vol. 2, No. 1, 01.01.2003, p. 15-21.

Research output: Contribution to journalArticle

@article{23f67f0755514ef480a2b1a304a5498f,
title = "Mild cognitive impairment: Prevalence, prognosis, aetiology, and treatment",
abstract = "Mild cognitive impairment (MCI) is a recently described syndrome that is currently thought of as a transition phase between healthy cognitive ageing and dementia. Although this notion seems to be reasonable, the general nature of the term MCI - including its many definitions - makes accurate accounting of the prevalence, prognosis, and potential benefit from treatment somewhat difficult. The differences in cognitive profile and clinical progression among individuals with MCI are generally recognised. However, recent evidence also suggests that the aetiological heterogeneity among individuals with MCI could be greater than previously reported. For example, cerebrovascular disease seems to be underestimated as a potential cause of MCI. In this review, I attempt to recognise workable definitions of MCI to discuss the prevalence, pathophysiology, prognosis, and possibilities for treatment of this disorder.",
author = "Charles DeCarli",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S1474-4422(03)00262-X",
language = "English (US)",
volume = "2",
pages = "15--21",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Mild cognitive impairment

T2 - Prevalence, prognosis, aetiology, and treatment

AU - DeCarli, Charles

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Mild cognitive impairment (MCI) is a recently described syndrome that is currently thought of as a transition phase between healthy cognitive ageing and dementia. Although this notion seems to be reasonable, the general nature of the term MCI - including its many definitions - makes accurate accounting of the prevalence, prognosis, and potential benefit from treatment somewhat difficult. The differences in cognitive profile and clinical progression among individuals with MCI are generally recognised. However, recent evidence also suggests that the aetiological heterogeneity among individuals with MCI could be greater than previously reported. For example, cerebrovascular disease seems to be underestimated as a potential cause of MCI. In this review, I attempt to recognise workable definitions of MCI to discuss the prevalence, pathophysiology, prognosis, and possibilities for treatment of this disorder.

AB - Mild cognitive impairment (MCI) is a recently described syndrome that is currently thought of as a transition phase between healthy cognitive ageing and dementia. Although this notion seems to be reasonable, the general nature of the term MCI - including its many definitions - makes accurate accounting of the prevalence, prognosis, and potential benefit from treatment somewhat difficult. The differences in cognitive profile and clinical progression among individuals with MCI are generally recognised. However, recent evidence also suggests that the aetiological heterogeneity among individuals with MCI could be greater than previously reported. For example, cerebrovascular disease seems to be underestimated as a potential cause of MCI. In this review, I attempt to recognise workable definitions of MCI to discuss the prevalence, pathophysiology, prognosis, and possibilities for treatment of this disorder.

UR - http://www.scopus.com/inward/record.url?scp=0042512345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042512345&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(03)00262-X

DO - 10.1016/S1474-4422(03)00262-X

M3 - Article

C2 - 12849297

AN - SCOPUS:0042512345

VL - 2

SP - 15

EP - 21

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 1

ER -